Overview

Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

Status:
Terminated
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase II trial is studying how well high-dose topotecan works as second-line therapy in treating patients with recurrent extensive-stage small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Case Comprehensive Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Topotecan